Company news

PDS Biotechnology Corporation news in 2023

PDS Biotechnology Corporation's news releases, calls and decks from 2023, newest first.

View company

PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer

November 27, 2023

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months

November 8, 2023

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results

November 6, 2023

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

October 22, 2023

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

October 10, 2023

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)

October 2, 2023

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

October 1, 2023

PDS Biotech to Present at the LD Micro Main Event XVI

September 25, 2023

PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101

September 24, 2023

PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

September 19, 2023

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

September 19, 2023

PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023

September 12, 2023

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference

September 5, 2023

PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting

August 15, 2023

PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update

August 13, 2023

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

August 13, 2023

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results

August 6, 2023

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023

August 1, 2023

PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023

July 24, 2023

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

July 16, 2023

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

July 10, 2023

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 29, 2023

PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

June 19, 2023

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

June 13, 2023

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

June 4, 2023

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

May 24, 2023

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

May 17, 2023

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

May 14, 2023

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

May 3, 2023

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

April 26, 2023

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

April 23, 2023

PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023

April 11, 2023

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

April 2, 2023

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

March 29, 2023

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

March 27, 2023

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

March 15, 2023

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

February 28, 2023

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

February 26, 2023

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

February 15, 2023

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

February 7, 2023

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

February 5, 2023

PDS Biotech Announces Participation in the Channelchek Takeaway Series

January 25, 2023

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

January 2, 2023

Calls in 2023

Decks in 2023